Muutke küpsiste eelistusi

E-raamat: Transfusion Medicine and Patient Safety [De Gruyter e-raamatud]

, ,
  • Formaat: 120 pages, 24 Illustrations, color; 18 Tables, black and white
  • Sari: Patient Safety
  • Ilmumisaeg: 20-Dec-2012
  • Kirjastus: De Gruyter
  • ISBN-13: 9783110287073
Teised raamatud teemal:
  • De Gruyter e-raamatud
  • Hind: 77,94 €*
  • * hind, mis tagab piiramatu üheaegsete kasutajate arvuga ligipääsu piiramatuks ajaks
Transfusion Medicine and Patient SafetySuurem pilt
  • Formaat: 120 pages, 24 Illustrations, color; 18 Tables, black and white
  • Sari: Patient Safety
  • Ilmumisaeg: 20-Dec-2012
  • Kirjastus: De Gruyter
  • ISBN-13: 9783110287073
Teised raamatud teemal:
Wiley OnlineRohkem infot De Gruyter e-raamatute kohta
Raamatu kodulehekülg: http://dx.doi.org/10.1515/9783110287073
Blood transfusion is considered a life-saving therapy since ancient times, but, at the same time, a high-risk procedure. Nowadays the common perception is that infection is the greatest risk, even if the blood has never been safer from this point of view. Currently, the residual risk of transfusion must be related mainly to immunological mechanisms underlying to AB0 and minor blood systems, to compatibility of blood transfused and to development of irregular antibodies in transfused patients.

"Transfusion Medicine and Patient Safety" aims to provide the basic of immunohematology to readers and to analyze the transfusional process highlighting the most critical points, thus more exposed to errors.

Screening on blood and blood components for infectious diseases along with the surveillance action on emerging viruses results in the drastic reduction of post-transfusion infection, together with the potential to further increase the level of security from infection through the inactivation of blood components. The text also describes the major diagnostic systems and organizational models that modern technology provides us with a correct immunohematological diagnosis and an appropriate trasfusional therapy.
Introduction 1(4)
1 Basics of transfusion medicine
5(34)
1.1 The ABO and Rh blood group systems
5(9)
1.2 Other blood group systems
14(5)
1.2.1 The MNSs system
15(1)
1.2.2 The P system
15(1)
1.2.3 The Lutheran system
15(1)
1.2.4 The Kell system
16(1)
1.2.5 The Lewis system
16(1)
1.2.6 The Duffy system
16(1)
1.2.7 The Kidd system
17(1)
1.2.8 The Diego system
17(1)
1.2.9 The Xg-a system
18(1)
1.2.10 The Dombrock system
18(1)
1.2.11 The Colton system
18(1)
1.2.12 The Chido/Rodgers system
18(1)
1.2.13 The Cromer system
18(1)
1.2.14 The l/i system
18(1)
1.3 Natural and immune antibodies
19(2)
1.4 Transfusion guidelines
21(18)
1.4.1 Indications for the transfusion of concentrated red blood cells
22(3)
1.4.2 Indications for the transfusion of platelet concentrates
25(1)
1.4.3 Indications for the transfusion of fresh frozen plasma
26(1)
1.4.4 Indications for the transfusion of leukodepleted blood components
27(1)
1.4.5 Indications for the transfusion of irradiated blood components
28(2)
1.4.6 Indications for granulocyte transfusions
30(1)
1.4.7 Virus-inactivated blood components
30(2)
1.4.8 Complications of transfusion therapy
32(7)
2 The transfusion process
39(20)
2.1 Blood donation
39(2)
2.2 Donating multiple blood components
41(1)
2.3 Preparation of blood and blood components
42(1)
2.4 The immunohematology laboratory
43(5)
2.5 The immunohematology laboratory
48(6)
2.5.1 Studying the Rh system
49(1)
2.5.2 Detecting allo-antibodies to red cell antigens
50(4)
2.6 Transfusion request forms and the administration of blood and blood components
54(5)
3 Automation and computerization of the transfusion process
59(18)
3.1 Automation as a safety factor
59(5)
3.2 Computerization of the transfusion process: from donor to patient
64(5)
3.3 The computerized transfusion network
69(2)
3.4 Hemovigilance
71(4)
3.5 What can be improved in the future?
75(2)
4 Biological validation of blood components
77(32)
4.1 Molecular and serological methods
77(11)
4.1.1 Serological investigations
78(1)
4.1.2 Molecular investigations
79(1)
4.1.3 Structure of the DNA
79(3)
4.1.4 Real-time PCR
82(2)
4.1.5 PCR-TMA
84(4)
4.2 Decision-making and the quality system
88(11)
4.3 Risk management versus patient safety: medicolegal considerations
99(10)
5 Error in transfusion medicine
109(4)
Index 113
Giustina de Silvestro, Azienda Ospedaliera di Padova, Padua, Italy; Arianna Veronesi, Azienda U.L.S.S. 15 "Alta Padovana", Padua, Italy; Maria Vicarioto, Azienda Ospedaliera di Padova, Padua, Italy.
Püsilink: https://www.kriso.ee/db/9783110287073_pe.html